Leavell Investment Management Inc. Sells 893 Shares of Gilead Sciences, Inc. $GILD

Leavell Investment Management Inc. trimmed its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 21.6% in the 2nd quarter, HoldingsChannel.com reports. The institutional investor owned 3,243 shares of the biopharmaceutical company’s stock after selling 893 shares during the quarter. Leavell Investment Management Inc.’s holdings in Gilead Sciences were worth $360,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently added to or reduced their stakes in GILD. Brighton Jones LLC grew its position in Gilead Sciences by 20.6% during the fourth quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company’s stock valued at $1,326,000 after buying an additional 2,450 shares during the period. Bison Wealth LLC bought a new position in shares of Gilead Sciences in the fourth quarter worth approximately $215,000. Golden State Wealth Management LLC boosted its position in shares of Gilead Sciences by 14.5% in the first quarter. Golden State Wealth Management LLC now owns 863 shares of the biopharmaceutical company’s stock worth $97,000 after purchasing an additional 109 shares during the period. Sovran Advisors LLC boosted its position in shares of Gilead Sciences by 23.0% in the first quarter. Sovran Advisors LLC now owns 6,838 shares of the biopharmaceutical company’s stock worth $715,000 after purchasing an additional 1,278 shares during the period. Finally, Hills Bank & Trust Co bought a new position in shares of Gilead Sciences in the first quarter worth approximately $131,000. 83.67% of the stock is currently owned by institutional investors.

Gilead Sciences Trading Down 0.4%

GILD stock opened at $120.47 on Tuesday. The company has a market capitalization of $149.48 billion, a PE ratio of 24.00, a P/E/G ratio of 0.83 and a beta of 0.34. Gilead Sciences, Inc. has a 12 month low of $86.08 and a 12 month high of $124.61. The firm’s 50-day moving average is $115.52 and its 200 day moving average is $111.21. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.32 and a quick ratio of 1.15.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 EPS for the quarter, beating analysts’ consensus estimates of $1.96 by $0.05. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The business had revenue of $7.08 billion for the quarter, compared to the consensus estimate of $6.95 billion. During the same quarter last year, the firm posted $2.01 EPS. The company’s revenue for the quarter was up 1.4% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. On average, research analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Insider Transactions at Gilead Sciences

In other Gilead Sciences news, CEO Daniel Patrick O’day sold 10,000 shares of Gilead Sciences stock in a transaction that occurred on Monday, September 29th. The shares were sold at an average price of $111.66, for a total transaction of $1,116,600.00. Following the completion of the sale, the chief executive officer directly owned 591,203 shares in the company, valued at approximately $66,013,726.98. The trade was a 1.66% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CFO Andrew D. Dickinson sold 2,500 shares of Gilead Sciences stock in a transaction that occurred on Wednesday, October 15th. The shares were sold at an average price of $118.08, for a total transaction of $295,200.00. Following the sale, the chief financial officer owned 157,055 shares of the company’s stock, valued at approximately $18,545,054.40. The trade was a 1.57% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 61,500 shares of company stock valued at $7,142,140 in the last 90 days. Insiders own 0.27% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on the stock. Royal Bank Of Canada upped their price target on shares of Gilead Sciences from $98.00 to $100.00 and gave the stock a “sector perform” rating in a research report on Wednesday, October 8th. JPMorgan Chase & Co. upped their target price on shares of Gilead Sciences from $135.00 to $145.00 and gave the stock an “overweight” rating in a research report on Tuesday, September 16th. Rothschild & Co Redburn upped their target price on shares of Gilead Sciences from $136.00 to $143.00 and gave the stock a “buy” rating in a research report on Friday, September 12th. TD Cowen upped their target price on shares of Gilead Sciences from $115.00 to $125.00 and gave the stock a “buy” rating in a research report on Thursday, October 23rd. Finally, Wolfe Research increased their price objective on shares of Gilead Sciences from $135.00 to $140.00 and gave the company an “outperform” rating in a research report on Thursday, October 23rd. One equities research analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating and six have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $122.61.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.